Stay updated on Cabozantinib vs Placebo in Radioiodine-Refractory Thyroid Cancer Clinical Trial
Sign up to get notified when there's something new on the Cabozantinib vs Placebo in Radioiodine-Refractory Thyroid Cancer Clinical Trial page.

Latest updates to the Cabozantinib vs Placebo in Radioiodine-Refractory Thyroid Cancer Clinical Trial page
- ChecktodayNo Change Detected
- Check8 days agoChange DetectedThe site update indicates a new software revision from v3.5.3 to v3.5.4, signaling an incremental platform upgrade. This change relates to the site’s underlying version and does not modify the visible content or features on the page.SummaryDifference0.0%

- Check15 days agoNo Change Detected
- Check22 days agoChange DetectedThe site revision has been updated from v3.5.2 to v3.5.3, indicating a new software release. This backend update does not alter the visible study details content on the page.SummaryDifference0.0%

- Check29 days agoChange DetectedUpdated the displayed region name for the Bordeaux site from “Nouvelle-Aquitaine” to “New Aquitaine,” while retaining the same city and postal code.SummaryDifference0.0%

- Check36 days agoChange DetectedRevision tag updated from v3.5.0 to v3.5.2 on the page.SummaryDifference0.0%

- Check43 days agoChange DetectedAdded Padova, Italy, 35128 and removed Padua, Italy, 35128 from the list of study locations.SummaryDifference0.0%

- Check51 days agoChange DetectedAdded the term Differentiated thyroid carcinoma and a Resources section linking the Genetic and Rare Diseases Information Center.SummaryDifference0.1%

Stay in the know with updates to Cabozantinib vs Placebo in Radioiodine-Refractory Thyroid Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Cabozantinib vs Placebo in Radioiodine-Refractory Thyroid Cancer Clinical Trial page.